Patients with seborrheic dermatitis intolerant to steroids achieve clearance with Zoryve

A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.
Zoryve foam 0.3% (roflumilast, Arcutis) is a once-daily steroid-free topical for the treatment of adults and adolescents with seborrheic dermatitis. According to data from this analysis, which was presented at the 2024 Winter Clinical Dermatology Conference, patients who were contraindicated, intolerant or unresponsive to steroid topicals were 3.5 times more

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.